The FDA's kinder, gentler attitude toward India hasn't stopped tough enforcement moves

The FDA may have been all smiles and pleasantries at a recent meeting with its counterparts in India, but that hasn't stopped it from taking serious action against the country's manufacturing plants. The latest: a ban on imports from two more Ipca Laboratories facilities. More from FiercePharmaAsia

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.